Market Intelligence, Clinical Progress, and High-Purity Reagents for RSK1 Inhibitor and Degrader Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RPS6KA1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RPS6KA1 Recombinant Protein (WT / Kinase Dead mutants) High purity (>90% by SDS-PAGE). Sequence Verified. Sf9 Insect Cell or HEK293 expressed. |
View RPS6KA1 Products |
| Gene Delivery | RPS6KA1 Promise-ORF / Lentivirus Full-length human RPS6KA1 ORF for stable expression and cell-based phosphorylation assays. |
View RPS6KA1 Products |
| Benchmark Ab | Anti-RPS6KA1 Control Antibody Recombinant monoclonal antibody for western blot, ELISA, and IP validation. |
View RPS6KA1 Products |
| Validator | RPS6KA1 siRNA Set Target-specific siRNA pools for gene knockdown and phenotype validation. |
View RPS6KA1 Products |
| Related Target A | RPS6KA3 (RSK2) Highly homologous isoform. Critical for counter-screening to ensure drug selectivity. |
View RPS6KA3 Products |
| Related Target B | MAPK1 (ERK2) Direct upstream kinase activator of RSK1. Essential for pathway-level inhibition studies. |
View MAPK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (RSK1 vs RSK2/3/4) | Sequence-verified, highly pure recombinant proteins for all four RSK isoforms available for parallel screening. |
| Covalent Inhibitor Binding Assays | Mass spectrometry-verified intact proteins ensuring correct cysteine residue availability for covalent targeting. |
| Lack of Controls | Validated benchmark antibodies and reference control inhibitors included in the development pipeline. |
| False Positives in Phenotypic Screening | Sequence-specific siRNA pools for target validation to confirm on-target cellular effects. |
Live RPS6KA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RPS6KA1 (RSK1) is gaining momentum within the MAPK/ERK pathway oncology landscape. Historically overshadowed by upstream targets like RAS, RAF, and MEK, RSK1 is now recognized as a critical node for overcoming acquired resistance to MEK and EGFR inhibitors. The therapeutic pipeline is transitioning from non-selective first-generation kinase inhibitors to highly selective covalent inhibitors and PROTAC degraders designed to minimize off-target toxicities associated with broader AGC kinase inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Covalent Small Molecules | Boehringer Ingelheim, Academic Spin-offs | Triple-Negative Breast Cancer (TNBC), Melanoma | Kinase assays requiring high-purity, active-conformation recombinant proteins. |
| PROTAC Degraders | Targeted Protein Degradation (TPD) Biotech | Prostate Cancer, Colorectal Cancer | Ubiquitination assays requiring stable protein constructs and target-specific siRNA for validation. |
| Combination Therapies | Novartis, AstraZeneca | KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) | Pathway reporter cell lines generated via high-titer Lentivirus transduction. |